Answers are grounded in this paper and cite their sources.
Immunoselection of a non-metastatic variant of the highly metastatic MDAY-D2 tumor of DBA/2 mice was achieved by means of an antiserum directed to the LY6.2 surface marker of MDAY-D2. While the new tumor (MDAY-D2.L61) expresses no detectable LY6.2, other measurable surface markers including H2d, FcR and TAA remain unchanged. The phenotypic behavior of MDAY-D2.L61 is that of a non-metastatic tumor and has remained stable after 1 year of maintenance in vivo and in vitro. Immunoselection can now be used to derive variants with stable phenotypic behavior from heterogeneous parent tumor cell populations.
No takes yet. Share an insight, caveat, or question.
Frost et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: